Lenacapavir binding to immature Gag induces giant virions and causes protease-dependent inhibition of viral release
Proceedings of the National Academy of Sciences, Volume 123, Issue 36, September 2026. SignificanceLenacapavir (LEN) is a long-acting therapy that targets the capsid of HIV, yet the mechanisms underlying its effects during the late stages of viral replication remain poorly understood. Here, we showed that LEN binds to precursor Gag…
bubmagSeptember 3, 2026